94.32
전일 마감가:
$90.92
열려 있는:
$92.5
하루 거래량:
1.09M
Relative Volume:
0.81
시가총액:
$7.39B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
-47.16
EPS:
-2
순현금흐름:
$-103.81M
1주 성능:
+2.30%
1개월 성능:
+26.21%
6개월 성능:
+124.46%
1년 성능:
+542.07%
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VRNA
Verona Pharma Plc Adr
|
94.32 | 7.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-28 | 개시 | TD Cowen | Buy |
2025-04-21 | 개시 | Cantor Fitzgerald | Overweight |
2025-01-10 | 개시 | ROTH MKM | Buy |
2024-10-03 | 개시 | Wells Fargo | Overweight |
2023-05-22 | 재개 | Jefferies | Buy |
2022-09-19 | 재개 | Wedbush | Outperform |
2022-08-26 | 개시 | Piper Sandler | Overweight |
2021-09-13 | 개시 | H.C. Wainwright | Buy |
2020-08-25 | 개시 | Jefferies | Buy |
2020-08-10 | 개시 | Canaccord Genuity | Buy |
2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data - Benzinga
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Verona Pharma stock soars to all-time high of $74.36 By Investing.com - Investing.com UK
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Shareholders Approve All Proposals at AGM By Investing.com - Investing.com South Africa
Verona Pharma Shareholders Approve All Proposals at AGM - Investing.com
A significant driver of top-line growth: Verona Pharma Plc ADR (VRNA) - Sete News
Is Astrazeneca plc ADR (AZN) positioned for future growth? - Sete News
Verona Pharma Plc ADR [VRNA] Records 50-Day SMA of $62.73 - knoxdaily.com
Tencent Music Entertainment Group ADR [TME] Officer makes an insider purchase of 1,036,363 shares worth 14.87 million. – Knox Daily - knoxdaily.com
TAL Education Group ADR [TAL] Officer makes an insider purchase of 24,041 shares worth 0.28 million. - knoxdaily.com
Ratios Uncovered: Breaking Down Verona Pharma Plc ADR (VRNA)’s Trailing Twelve Months Metrics - DWinneX
Verona Pharma Plc ADR (VRNA) is a good investment, but the stock may be overvalued - uspostnews.com
What is the investor’s view on Marriott Vacations Worldwide Corp (VAC)? - uspostnews.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Financial Health Report: Alamos Gold Inc (AGI)’s Ratios Tell a Tale - DWinneX
Cantor Fitzgerald sets $80 target on Verona Pharma stock By Investing.com - Investing.com South Africa
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit undervalued - uspostnews.com
Verona Pharma Plc ADR [VRNA] Rickard Kathleen A. sells 79,264 Shares for $0.66 million - knoxdaily.com
Verona Pharma Plc ADR [VRNA] Chief Medical Officer makes an insider purchase of 79,264 shares worth 0.66 million. - knoxdaily.com
Verona Pharma secures $450 million credit facility on better terms By Investing.com - Investing.com South Africa
Verona Pharma secures $450 million credit facility on better terms - Investing.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com
The growth track for Cracker Barrel Old Country Store Inc (CBRL) has changed recently - SETE News
Verona Pharma Plc ADR (NASDAQ: VRNA) Up 298.80% This Year: What Is Going To Happen Next - Stocks Register
Verona Pharma’s chief medical officer sells shares worth $661,941 - Investing.com India
Verona Pharma’s chief medical officer sells shares worth $661,941 By Investing.com - Investing.com South Africa
Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily
McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily
Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily
Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verona Pharma Plc Adr 주식 (VRNA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Fisher Andrew | General Counsel |
Jun 16 '25 |
Sale |
11.53 |
80,000 |
922,000 |
359,999 |
Hahn Mark W | Chief Financial Officer |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,360 |
12,278,992 |
ZACCARDELLI DAVID | President and CEO |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,520 |
13,190,168 |
자본화:
|
볼륨(24시간):